期刊文献+
共找到8,148篇文章
< 1 2 250 >
每页显示 20 50 100
中晚期鼻咽癌新辅助化疗联合放疗前瞻性临床试验的长期结果 被引量:166
1
作者 马骏 麦海强 +3 位作者 洪明晃 闵华庆 毛志达 崔念基 《癌症》 SCIE CAS CSCD 北大核心 2001年第5期505-510,共6页
目的:评价新辅助化疗联合放疗在中晚期鼻咽癌治疗中的价值。方法:前瞻性临床试验采用化疗方案:Cisplatin20mg/m2,1~5天,5FU500mg/m2,1~5天,BLM7mg/m2,第1、5天,化疗2~3个疗程。放射治疗鼻咽剂量:66~74Gy/33~37次,共7~9周;颈部淋... 目的:评价新辅助化疗联合放疗在中晚期鼻咽癌治疗中的价值。方法:前瞻性临床试验采用化疗方案:Cisplatin20mg/m2,1~5天,5FU500mg/m2,1~5天,BLM7mg/m2,第1、5天,化疗2~3个疗程。放射治疗鼻咽剂量:66~74Gy/33~37次,共7~9周;颈部淋巴结剂量:60~70Gy/30~35次,共7~8.5周;颈部预防量:48~50Gy。结果:1992~1993年457例鼻咽癌病人进入研究,17例因各种原因退出队列,440例进入分析(化疗+放疗组219例、单纯放疗组221例)。5年生存率及无瘤生存率实验组及对照组分别为62%vs55%P=0.1335及58%vs48%P=0.0539。5年无局部复发生存率及无远处转移生存率两组分别为82%vs74%P=0.0412及79%vs75%(P=0.4177。亚组分析显示新辅助化疗能明显提高T3~4期的局控率;对N2~3病人的远处转移率无影响。结论:新辅助化疗未能提高中晚期鼻咽癌病人的总生存率,亦未能降低远处转移率,有提高无瘤生存率的趋势。新辅助化疗的指征:T3~4期病人。 展开更多
关键词 鼻咽肿瘤 化学疗法 放射疗法 生存分析
下载PDF
The prevalence and prevention of nasopharyngeal carcinoma in China 被引量:138
2
作者 Malcolm J. Simons 《Chinese Journal of Cancer》 SCIE CAS CSCD 北大核心 2011年第2期114-119,共6页
Nasopharyngeal carcinoma (NPC) has remarkable epidemiological features, including regional, racial, and familial aggregations. The aim of this review is to describe the epidemiological characteristics of NPC and to pr... Nasopharyngeal carcinoma (NPC) has remarkable epidemiological features, including regional, racial, and familial aggregations. The aim of this review is to describe the epidemiological characteristics of NPC and to propose possible causes for the high incidence patterns in southern China. Since the etiology of NPC is not completely understood, approaches to primary prevention of NPC remain under consideration. This situation highlights the need to conduct secondary prevention, including improving rates of early detection, early diagnosis, and early treatment in NPC patients. Since the 1970's, high-risk populations in southern China have been screened extensively for early detection of NPC using anti-Epstein-Barr virus (EBV) serum biomarkers. This review summarizes several large screening studies that have been conducted in the high-incidence areas of China. Screening markers, high-risk age range for screening, time intervals for blood re-examination, and the effectiveness of these screening studies will be discussed. Conduction of prospective randomized controlled screening trials in southern China can be expected to maximize the cost-effectiveness of early NPC detection screening. 展开更多
关键词 中国南部 鼻咽癌 预防 全国人民代表大会 流行病学特点 筛选标记 早期治疗 随机对照试验
下载PDF
鼻咽癌患者放疗后张口困难及其影响因素 被引量:101
3
作者 陈明 曾祥发 +6 位作者 赵充 吴少雄 黄晓延 韩非 罗伟 卢泰祥 崔念基 《癌症》 SCIE CAS CSCD 北大核心 2001年第6期651-653,共3页
目的:观察鼻咽癌患者放疗后张口困难的情况,探讨影响放射性颞颌关节损伤的有关因素。方法:选择352例常规分割放疗结束后≥6个月的鼻咽癌病例,所有病例颞颌关节受照总剂量为51.90~78.89 Gy,总疗程35~141天... 目的:观察鼻咽癌患者放疗后张口困难的情况,探讨影响放射性颞颌关节损伤的有关因素。方法:选择352例常规分割放疗结束后≥6个月的鼻咽癌病例,所有病例颞颌关节受照总剂量为51.90~78.89 Gy,总疗程35~141天。以门齿距为观察张口困难的指标,组间差异采用卡方检验,张口困难发生率与颞颌关节受照剂量关系采用二元曲线拟合,多变量分析采用Logistic回归。结果:全组张口困难发生率58.5%,重度张口困难发生率7.1%;颞颌关节受照剂量为51. 90-60. 00 Gy、> 60. 00~70. 00 Gy、> 70. 00~78. 89 Gy的病人张口困难发生率分别为 46.4%、 53 5%和 62. 3%(P=0. 050);放疗后坚持张口锻炼和未锻炼者发生率分别为51. 6%和 61. 7%(P=0.028);年龄≤42岁组和>42岁组发生率分别为54.1%和62.75(P=0.040);颌关节受照剂量、张口锻炼与否和年龄大小是放射性颞颌关节损伤的独立影响因素。结论:鼻咽癌病人放疗后张口困难的发生率较高,颞颌关节受照剂量、张口锻炼和病人年龄是主要的影响因素。鼻咽靶区全部剂量都从两颞侧给予的照射方式应设法予以改进。 展开更多
关键词 鼻咽肿瘤 放射疗法 颞颌关节 放射损伤
下载PDF
Nasopharyngeal carcinoma incidence and mortality in China,2013 被引量:77
4
作者 Kuang-Rong Wei Rong-Shou Zheng +3 位作者 Si-Wei Zhang Zhi-Heng Liang Zhu-Ming Li Wan-Qing Chen 《Chinese Journal of Cancer》 SCIE CAS CSCD 2017年第12期686-693,共8页
Background: We estimated the incidence and mortality of nasopharyngeal carcinoma(NPC) in China in 2010 according to the data of 145 domestic population-based cancer registries in 2014, and no such reports since then.H... Background: We estimated the incidence and mortality of nasopharyngeal carcinoma(NPC) in China in 2010 according to the data of 145 domestic population-based cancer registries in 2014, and no such reports since then.Hence, to further and better understand its epidemiology in China and to provide more precise scientific information for its control and prevention in China, we analyzed the NPC incidence and mortality of 255 domestic populationbased cancer registries, and estimated the national rates in 2013 again.Methods: NPC incidence and mortality data of 255 domestic cancer registries in 2013, accepted by the 2016 National Cancer Registry Annual Report, were collected and collated, and the indices of NPC such as the numbers of new cases and deaths, crude rates, age-standardized rates, and truncated rates of incidence and mortality were calculated and analyzed. The incidence and mortality in China and its constituent areas were estimated according to the national population in 2013.Results: An estimated 42,100 new cases and 21,320 deaths were attributed to NPC in China in 2013, accounting for1.14% of all new cancer cases and 0.96% of all cancer-related deaths that year in China. Crude incidence and mortality of NPC were 3.09/100,000 and 1.57/100,000, respectively. World age-standardized incidence and mortality were2.17/100,000 and 1.08/100,000, respectively. The incidence and mortality of males were obviously higher than those of females and slightly higher in urban areas than in rural areas. Among seven Chinese administrative regions, NPC incidence and mortality were obviously higher in South China than in other regions and lowest in North China. Top3 incidence and mortality provinces and registering areas all located in South China. The age-specific incidence and mortality rose quickly from age 25-29 and 35 to 39 years, respectively, peaked at different ages and varied by location.Conclusions: These results demonstrated that NPC incidence and mortality in China in 2013 were also at high levels worldwide, which s 展开更多
关键词 nasopharyngeal carcinoma INCIDENCE MORTALITY China
下载PDF
鼻咽癌治疗的研究进展 被引量:74
5
作者 马骏 《中山大学学报(医学科学版)》 CAS CSCD 北大核心 2010年第2期179-185,共7页
调强放射治疗技术提高了鼻咽癌的局部区域性控制率和总生存率,并改善了生存质量,而准确勾画靶区是保证鼻咽癌调强疗效的前提。近年临床研究结果逐渐支持以同步放化疗作为局部晚期鼻咽癌的标准治疗方式,但诱导化疗和辅助化疗的价值尚有... 调强放射治疗技术提高了鼻咽癌的局部区域性控制率和总生存率,并改善了生存质量,而准确勾画靶区是保证鼻咽癌调强疗效的前提。近年临床研究结果逐渐支持以同步放化疗作为局部晚期鼻咽癌的标准治疗方式,但诱导化疗和辅助化疗的价值尚有待明确。鼻咽癌的分子靶向药物治疗主要处在Ⅰ、Ⅱ临床试验阶段,为今后的综合治疗模式提供了更多的选择。本文就这三方面的研究进展作一综述。 展开更多
关键词 鼻咽癌 调强放射治疗 化学治疗 分子靶向治疗
下载PDF
14株(亚株)人鼻咽癌细胞的放射生物特性(英文) 被引量:49
6
作者 夏云飞 李满枝 +4 位作者 黄冰 陈剑经 李志强 汪惠民 William A.Brook 《癌症》 SCIE CAS CSCD 北大核心 2001年第7期683-687,共5页
目的:了解14株(亚株)人鼻咽癌细胞的放射生物学特性。材料与方法:采用集落存活分析法分析中国建成的14株(亚株)人鼻咽癌细胞的特性;除了CNE1之外,所有的细胞均为低分化鳞癌细胞,实验求得的放射剂量存活曲线用线性二次模型进行... 目的:了解14株(亚株)人鼻咽癌细胞的放射生物学特性。材料与方法:采用集落存活分析法分析中国建成的14株(亚株)人鼻咽癌细胞的特性;除了CNE1之外,所有的细胞均为低分化鳞癌细胞,实验求得的放射剂量存活曲线用线性二次模型进行拟合,用Fertil 和Malais 介绍的方法和原理计算存活曲线的初斜率(α),平均抑制剂量(mean inactivation dose, MID)及2 Gy处的存活分数(SF2)。结果:α:0.001~0.81, MID:1.11~2.46, SF2:0.17~0.66, 14株(亚株)鼻咽癌细胞的放射敏感性变化较大,来源同一个母株(SUNE1)的8个亚株之间的放射敏感性存在着差别。结论:鼻咽癌细胞在个体内和个体间变化较大;因此,在临床制定鼻咽癌的治疗计划时,要考虑鼻咽癌的个体放射生物学特性。 展开更多
关键词 鼻咽癌 细胞株 放射生物学
下载PDF
鼻咽癌家系体质调查研究 被引量:42
7
作者 周小军 田道法 《中国中医基础医学杂志》 CAS CSCD 2002年第11期60-63,共4页
目的 :调查鼻咽癌患者及其家系成员的中医体质类型分布情况。方法 :运用中医体质调查表 ,对 16名初诊鼻咽癌患者、38名放疗后鼻咽癌患者、119名鼻咽癌核心家系成员及 98名家系成员之配偶 (作为对照 )的体质类型进行调查。采用SPSS(10 ... 目的 :调查鼻咽癌患者及其家系成员的中医体质类型分布情况。方法 :运用中医体质调查表 ,对 16名初诊鼻咽癌患者、38名放疗后鼻咽癌患者、119名鼻咽癌核心家系成员及 98名家系成员之配偶 (作为对照 )的体质类型进行调查。采用SPSS(10 0 )进行统计分析。结果 :鼻咽癌家系成员体质以虚弱质为特点 ,而鼻咽癌放疗后患者以虚热及虚瘀体质为特点。回归分析显示 ,虚弱质为家系成员的主要体质高危因素 ,虚热及虚瘀体质、癌家族史及嗜食腌熏食品为鼻咽癌患者发病相关的主要危险诱因。结论 :虚弱质是鼻咽癌发生的首要内因和基本体质 ,而在鼻咽癌形成后及治疗中则出现虚热及虚瘀体质。 展开更多
关键词 鼻咽癌 家系体质调查 体质证型
下载PDF
调强放疗结合诱导化疗或同期加辅助化疗治疗局部晚期鼻咽癌的疗效比较 被引量:50
8
作者 丘文泽 黄培钰 +3 位作者 施君理 夏海群 赵充 曹卡加 《中国肿瘤临床》 CAS CSCD 北大核心 2015年第4期231-235,共5页
目的:比较诱导化疗加调强放疗和同期放化疗加辅助化疗治疗局部晚期鼻咽癌的疗效。方法:收集2004年1月至2008年12月中山大学肿瘤医院收治的经病理证实的局部晚期鼻咽癌240例,其中采用顺铂+5-FU诱导化疗加调强放疗(诱导组)117例,采用顺铂... 目的:比较诱导化疗加调强放疗和同期放化疗加辅助化疗治疗局部晚期鼻咽癌的疗效。方法:收集2004年1月至2008年12月中山大学肿瘤医院收治的经病理证实的局部晚期鼻咽癌240例,其中采用顺铂+5-FU诱导化疗加调强放疗(诱导组)117例,采用顺铂、调强放疗同期放化疗加顺铂+5-FU辅助化疗(同期组)123例。应用Kaplan-Meier和Log-rank法计算和比较两组患者的生存率。结果:诱导组和同期组的5年总生存率、无瘤生存率、无转移生存率、无鼻咽复发生存率和无颈部复发生存率分别为78.0%和78.7%、68.9%和67.5%、79.0%和77.0%、91.6%和91.0%、95.3%和93.7%,两组比较差异无统计学意义(P>0.05)。同期组Ⅲ、Ⅳ级恶心呕吐和白细胞减少的发生率明显高于诱导组。多因素分析结果显示N分期和年龄是影响局部晚期鼻咽癌患者总生存的预后独立因素。结论:诱导化疗加调强放疗治疗局部晚期鼻咽癌的疗效达到同期放化疗加辅助化疗的水平,远处转移是局部晚期鼻咽癌治疗失败的主要原因。 展开更多
关键词 鼻咽癌 调强放疗 诱导化疗 同期放化疗 辅助化疗
下载PDF
鼻咽癌放疗后并发症的预防与护理进展 被引量:50
9
作者 苗青 杜文静 《护理研究(上旬版)》 2010年第2期285-287,共3页
放疗是鼻咽癌的主要治疗手段,综述了近年来鼻咽癌放疗后并发症的预防与护理对策方面的新进展。
关键词 鼻咽癌 放射治疗 并发症 预防 护理
下载PDF
早期鼻咽癌三维适形、常规和传统外照射计划的剂量学评价 被引量:47
10
作者 罗伟 邓小武 卢泰祥 《癌症》 SCIE CAS CSCD 北大核心 2004年第5期605-608,共4页
背景和目的:传统鼻咽癌外照射技术存在不少的缺陷,改进鼻咽癌外照射技术已成为提高鼻咽癌疗效的一个努力方向,本研究利用三维治疗计划系统对鼻咽癌传统、常规和三维适形放疗(3DCRT)计划作剂量学比较,评估采用不同方法的意义。方法:选择2... 背景和目的:传统鼻咽癌外照射技术存在不少的缺陷,改进鼻咽癌外照射技术已成为提高鼻咽癌疗效的一个努力方向,本研究利用三维治疗计划系统对鼻咽癌传统、常规和三维适形放疗(3DCRT)计划作剂量学比较,评估采用不同方法的意义。方法:选择22例早期鼻咽癌患者,用三维治疗计划系统对每例患者分别作出传统、常规和3DCRT计划设计,然后根据靶区覆盖率(V95)、正常组织受量(D50,D33和D5等)和正常组织并发症发生率(NTCP)比较这三种计划。结果:剂量学比较表明,三种不同计划的PTVnx60和PTVnx50的V95分别为90.29%和77.67%(传统)、98.44%和98.85%(常规)、99.98%和99.63%(3DCRT),3DCRT和常规放疗有满意的V95,尤其是在亚临床病灶范围,两者均优于传统放疗;在正常组织保护方面,3DCRT和常规治疗计划均比传统方式能更好地保护脑干、颞叶、视交叉和垂体,而3DCRT比常规和传统方式更好地保护了腮腺和颞颌关节。结论:三种计划设计方式中,3DCRT和常规方法均有很好的V95,尤其是在亚临床病灶方面,而3DCRT治疗早期鼻咽癌的优势在于给予靶区特别是亚临床病灶区相同的剂量分布的前提下,可以比常规和传统方法减少某些正常组织器官如腮腺、颞颌关节等的照射剂量。 展开更多
关键词 早期鼻咽癌 三维适形 常规照射 传统外照射计划 剂量学评价
下载PDF
Incidence trend of nasopharyngeal carcinoma from 1987 to 2011 in Sihui County,Guangdong Province,South China:an age-period-cohort analysis 被引量:48
11
作者 Li-Fang Zhang Yan-Hua Li +5 位作者 Shang-Hang Xie Wei Ling Sui-Hong Chen Qing Liu Qi-Hong Huang Su-Mei Cao 《Chinese Journal of Cancer》 SCIE CAS CSCD 2015年第8期350-357,共8页
Introduction:In the past several decades,declining incidences of nasopharyngeal carcinoma(NPC) have been observed in Chinese populations in Hong Kong,Taiwan,Los Angeles,and Singapore.A previous study indicated that th... Introduction:In the past several decades,declining incidences of nasopharyngeal carcinoma(NPC) have been observed in Chinese populations in Hong Kong,Taiwan,Los Angeles,and Singapore.A previous study indicated that the incidence of NPC in Sihui County,South China remained stable until 2002,but whether age,diagnosis period,and birth cohort affect the incidence of NPC remains unknown.Methods:Age-standardized rates(ASRs) of NPC incidence based on the world standard population were examined in both males and females in Sihui County from 1987 to 2011.Joinpoint regression analysis was conducted to quantify the changes in incidence trends.A Poisson regression age-period-cohort model was used to assess the effects of age,diagnosis period,and birth cohort on the risk of NPC.Results:The ASRs of NPC incidence during the study period were 30.29/100,000 for males and 13.09/100,000 for females.The incidence of NPC remained stable at a non-significant average annual percent change of 0.2%for males and-1.6%for females throughout the entire period.A significantly increased estimated annual percent change of 6.8%(95%confidence interval,0.1%-14.0%) was observed from 2003 to 2009 for males.The relative risk of NPC increased with advancing age up to 50-59 and decreased at ages >60 years.The period effect curves on NPC were nearly flat for males and females.The birth cohort effect curve for males showed an increase from the1922 cohort to the 1957 cohort and a decrease thereafter.In females,there was an undulating increase in the relative risk from the 1922 cohort to the 1972 cohort.Conclusions:The incidence trends for NPC remained generally stable in Sihui from 1987 to 2011,with an increase from 2003 to 2009.The relative risks of NPC increased in younger females. 展开更多
关键词 队列分析 中国人群 发病率 鼻咽癌 广东省 全国人民代表大会 龄期 回归分析
下载PDF
779例鼻咽癌颈部淋巴结转移规律分析 被引量:47
12
作者 陈奇松 林少俊 +5 位作者 潘建基 张瑜 林锦 陈英 宗井凤 卢涛 《中国癌症杂志》 CAS CSCD 北大核心 2010年第1期50-54,共5页
背景与目的:鼻咽癌颈部淋巴结转移不仅影响临床分期及治疗计划,也是影响预后的主要因素之一。本研究旨在探讨鼻咽癌颈淋巴结转移的规律,为临床治疗及研究提供依据。方法:779例经病理证实的首诊鼻咽癌患者,治疗前均行MRI规范扫描,并根据... 背景与目的:鼻咽癌颈部淋巴结转移不仅影响临床分期及治疗计划,也是影响预后的主要因素之一。本研究旨在探讨鼻咽癌颈淋巴结转移的规律,为临床治疗及研究提供依据。方法:779例经病理证实的首诊鼻咽癌患者,治疗前均行MRI规范扫描,并根据影像学颈部淋巴结分区标准(RTOG2006版N+为基础)确定淋巴结位置。MRI资料分析由放疗科与影像科医师共同完成。以卡方检验分析不同T分期各区淋巴结转移率的差别及淋巴结不同直径之间包膜受侵的差别,同时分析淋巴结在各区分布特点及跳跃性转移情况。结果:本组患者中有592例(76.0%)出现转移淋巴结,各区分布如下:Ⅰ区1例(0.2%),Ⅱa区384例(64.9%),Ⅱb区499例(84.3%),Ⅲ区184例(31.1%),Ⅳ区33例(5.6%),Ⅴa区67例(11.3%),Ⅴb区21例(3.5%),咽后597例(76.6%)。本组各区最多转移淋巴结共1479个,其中包膜外侵973个(65.79%),包膜外侵比例随淋巴结直径增大而增大(P=0.000)。各区淋巴结转移和T分期之间无明显相关性,跳跃性转移率为1.0%。结论:鼻咽癌Ⅱ区和咽后淋巴结转移率最高,均为前哨淋巴结。Ⅰ区转移率极低。淋巴结包膜外侵比例与最大径正相关。淋巴结很少跳跃性转移,T分期和各区淋巴结转移之间无相关性。 展开更多
关键词 鼻咽癌 淋巴结 磁共振成像
下载PDF
精细定位和克隆9p21-22区域内鼻咽癌候选抑瘤基因 被引量:34
13
作者 阳剑波 宾亮华 +7 位作者 李忠花 张小慧 钱骏 张必成 周鸣 谢奕 邓龙文 李桂源 《癌症》 SCIE CAS CSCD 北大核心 2000年第1期6-9,共4页
目的:进一步精细限定鼻咽癌9p21-22区域等位基因杂合性丢失的频率和范围,筛选和克隆其共同缺失区内鼻咽癌相关的候选抑瘤基因。方法:应用11个定位于 9p21-22区域的高密度微卫星位点,检测 25例低分化鼻咽癌患者的... 目的:进一步精细限定鼻咽癌9p21-22区域等位基因杂合性丢失的频率和范围,筛选和克隆其共同缺失区内鼻咽癌相关的候选抑瘤基因。方法:应用11个定位于 9p21-22区域的高密度微卫星位点,检测 25例低分化鼻咽癌患者的杂合性丢失,确定其共同缺失区;用RT-PCR和Northern筛出在鼻咽癌细胞株HNE1和鼻咽癌活检组织中表达下调的、定位于共同缺失区内的 3’末端ESTs(Express Sequence Tags);采用 RACE技术和生物信息学资源克隆出候选EST的全长cDNA。结果: 25例患者中有17例(68%)存在一个或多个位点的杂合性丢失,其中D9s161(35.0%,7/20),D9S1678(31.5%,6/19),D9S263(3.3%,6/18)和D9S1853(33.3%,7/21)四个紧邻位点的丢失频率相对较高,并发现六位患者在该四个位点表现为连续性缺失;筛选D9S161-D9S1853区域内25个代表新基因的3’末端ESTs序列,发现一个EST(dbEST:208825)在鼻咽癌细胞株HNE1及73%(11/15)的活检组织中表达降低, Multiple Tissue Nort 展开更多
关键词 鼻咽肿瘤 染色体 9p21-22 杂合性丢失 克隆
下载PDF
鼻咽癌高危人群体质调查研究 被引量:44
14
作者 周小军 田道法 《中国中医基础医学杂志》 CAS CSCD 2003年第8期51-54,共4页
目的 :调查鼻咽癌高危人群体质类型分布情况。方法 :运用中医体质调查表 ,对 4 0名鼻咽癌高危人群 ,16名初诊鼻咽癌患者 ,38名放疗一年后鼻咽癌患者 ,74名EB病毒阴性之鼻咽炎患者及 4 4名EB病毒低度阳性之鼻咽炎患者的体质类型进行调查... 目的 :调查鼻咽癌高危人群体质类型分布情况。方法 :运用中医体质调查表 ,对 4 0名鼻咽癌高危人群 ,16名初诊鼻咽癌患者 ,38名放疗一年后鼻咽癌患者 ,74名EB病毒阴性之鼻咽炎患者及 4 4名EB病毒低度阳性之鼻咽炎患者的体质类型进行调查。采用SPSS(10 0 )进行统计分析。结果 :鼻咽癌高危人群体质以单纯气虚质为特点 ;初诊鼻咽癌患者体质以热和瘀为特点 ;放疗一年后鼻咽癌患者体质以气虚质为基础的夹热、夹瘀及夹湿为特点。结论 :气虚质是鼻咽癌的敏感体质且贯穿于鼻咽癌发生的全过程。 展开更多
关键词 鼻咽癌 高危人群 体质 气虚 EB病毒
下载PDF
时辰诱导化疗序贯同步放化疗治疗局部晚期鼻咽癌的Ⅱ期临床研究 被引量:47
15
作者 李媛媛 金风 +7 位作者 吴伟莉 陈海霞 龙金华 龚修云 陈国焱 毕婷 李卓林 贺前勇 《中国肿瘤临床》 CAS CSCD 北大核心 2013年第15期914-918,共5页
目的:研究TPF(多西他赛+顺铂+5-氟尿嘧啶)方案时辰诱导化疗联合调强放疗治疗局部晚期鼻咽癌的毒性反应和近期疗效。方法:初治的局部晚期鼻咽癌患者,接受诱导化疗TPF方案,多西紫杉醇75mg/m^2,静滴,d1。顺铂75mg/m^2,分5d完... 目的:研究TPF(多西他赛+顺铂+5-氟尿嘧啶)方案时辰诱导化疗联合调强放疗治疗局部晚期鼻咽癌的毒性反应和近期疗效。方法:初治的局部晚期鼻咽癌患者,接受诱导化疗TPF方案,多西紫杉醇75mg/m^2,静滴,d1。顺铂75mg/m^2,分5d完成静滴给药,每天10:00~22:00。5-氟尿嘧啶750mg/m^2/d d1—d5,持续静滴,每天22:00~10:00。21d/周期,共3个周期。随后行三维适形调强放疗(IMRT),放疗同期行紫杉醇单药增敏化疗(紫杉醇135mg/m^2,静滴,21天/周期,共2个周期)。不良反应按CTCAEv3.0评价分级,临床疗效参照2000年实体瘤治疗疗效评价标准(RECIST)进行评价,有效率为CR+PR。结果:3个周期诱导化疗后CR为23.8%,PR为68.6%。诱导化疗序贯同步放化疗后CR为64.8%,PR为31.4%。2年总生存率91.4%,2年无进展生存率87.0%,2年无远处转移生存率88.4%。诱导化疗主要不良反应为骨髓毒性,3级以上粒细胞下降为28.6%,无3级以上肾功能损害。同期放化疗期间口腔黏膜反应最多见为81.0%,其中16.2%出现3~4级反应。整组患者无治疗相关死亡。结论:TPF方案时辰诱导化疗联合紫杉醇同期调强放化疗治疗局部晚期鼻咽癌安全、近期疗效好,远期疗效及不良反应尚需扩大病例数及继续随访. 展开更多
关键词 鼻咽癌 诱导化疗 时辰化疗 适形调强放射治疗 同期放化疗
下载PDF
Nasopharyngeal carcinoma incidence and mortality in China in 2010 被引量:46
16
作者 Kuang-Rong Wei Rong-Shou Zheng +3 位作者 Si-Wei Zhang Zhi-Heng Liang Zhi-Xiong Ou Wan-Qing Chen 《Chinese Journal of Cancer》 SCIE CAS CSCD 2014年第8期381-387,共7页
Nasopharyngeal carcinoma(NPC) is common in South China. Although regional epidemiological data on NPC in China is available, national epidemiological data have been unavailable up to now. The goal of this study was to... Nasopharyngeal carcinoma(NPC) is common in South China. Although regional epidemiological data on NPC in China is available, national epidemiological data have been unavailable up to now. The goal of this study was to analyze the NPC incidence and mortality data in some domestic cancer registries, estimate these rates in China in 2010, and provide scientific information that can be harnessed for NPC control and prevention. To accomplish this goal, NPC incidence and mortality data for 2010 were collected from 145 Chinese cancer registries from which data were included in the 2013 National Cancer Registry Annual Report. Such indices as its incident and death numbers, crude rates, age-standardized rates and truncated rates were calculated and analyzed. The incidence and mortality in China and constituent areas were estimated according to the national population in 2010. An estimated 41,503 new cases and 20,058 deaths were attributed to NPC in China in 2010, accounting for 1.34% of all new cancer cases and 1.03% of all cancer-related deaths that year in China. Crude incidence and mortality were 3.16/100,000 and 1.53/100,000, respectively. World age-standardized incidence and mortality were 2.44/100,000 and 1.18/100,000, respectively. Incidence and mortality were higher among males than among females and slightly higher in urban areas than in rural areas. Among seven Chinese administrative regions, NPC incidence and mortality were obviously higher in South China than in other regions and lowest in North China. The male and female age-specific incidence and mortality both rose quickly from age 25-29 years, but peaked at different ages and varied by location. These results demonstrated that NPC incidence and mortality in China especially in South China were at high levels in the world, and suggested that control and prevention efforts should be enhanced. 展开更多
关键词 中国南方 死亡率 发病率 鼻咽癌 全国人民代表大会 人口估计 流行病学 控制工作
下载PDF
Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy 被引量:42
17
作者 Yan-Ping Mao Ling-Long Tang +7 位作者 Lei Chen Ying Sun Zhen-Yu Qi Guan-Qun Zhou Li-Zhi Liu Li Li Ai-Hua Lin Jun Ma 《Chinese Journal of Cancer》 SCIE CAS CSCD 2016年第12期673-682,共10页
Background: The prognostic values of staging parameters require continual re?assessment amid changes in diag?nostic and therapeutic methods. This study aimed to identify the prognostic factors and failure patterns of ... Background: The prognostic values of staging parameters require continual re?assessment amid changes in diag?nostic and therapeutic methods. This study aimed to identify the prognostic factors and failure patterns of non?meta?static nasopharyngeal carcinoma(NPC) in the intensity?modulated radiotherapy(IMRT) era.Methods: We reviewed the data from 749 patients with newly diagnosed, biopsy?proven, non?metastatic NPC in our cancer center(South China, an NPC endemic area) between January 2003 and December 2007. All patients under?went magnetic resonance imaging(MRI) before receiving IMRT. The actuarial survival rates were estimated using the Kaplan–Meier method, and survival curves were compared using the log?rank test. Multivariate analyses with the Cox proportional hazards model were used to test for the independent prognostic factors by backward eliminating insigniicant explanatory variables.Results: The 5?year occurrence rates of local failure, regional failure, locoregional failure, and distant failure were 5.4, 3.0, 7.4, and 17.4%, respectively. The 5?year survival rates were as follows: local relapse?free survival, 94.6%; nodal relapse?free survival, 97.0%; distant metastasis?free survival, 82.6%; disease?free survival, 75.1%; and overall survival, 82.0%. Multivariate Cox regression analysis revealed that orbit involvement was the only signiicant prognostic fac?tor for local failure(P = 0.011). Parapharyngeal tumor extension, retropharyngeal lymph node involvement, and the laterality, longest diameter, and Ho's location of the cervical lymph nodes were signiicant prognostic factors for both distant failure and disease failure(all P < 0.05). Intracranial extension had signiicant prognostic value for distant failure(P = 0.040).Conclusions: The key failure pattern for NPC was distant metastasis in the IMRT era. With changes in diagnostic and therapeutic technologies as well as treatment modalities, the signiicant prognostic parameters for local control have also been altered substantially. 展开更多
关键词 nasopharyngeal carcinoma Intensity-modulated radiotherapy PROGNOSIS Failure pattern Tumor staging
下载PDF
奈达铂或顺铂联合紫杉醇同步放化疗局部晚期鼻咽癌的疗效比较 被引量:43
18
作者 邓颖 邓春美 +4 位作者 胡洪林 任刚 杨兰 潘海霞 朱学强 《实用癌症杂志》 2011年第2期175-177,共3页
目的探讨奈达铂替代顺铂与紫杉醇联合同步放化疗局部晚期鼻咽癌的疗效及患者耐受性。方法实验组(TN组)30例,采用紫杉醇135 mg/m2静脉滴注d1+奈达铂100 mg/m2静脉滴注第1天诱导化疗,每3周为1个化疗周期,共2个疗程,以后行同样方案同期放化... 目的探讨奈达铂替代顺铂与紫杉醇联合同步放化疗局部晚期鼻咽癌的疗效及患者耐受性。方法实验组(TN组)30例,采用紫杉醇135 mg/m2静脉滴注d1+奈达铂100 mg/m2静脉滴注第1天诱导化疗,每3周为1个化疗周期,共2个疗程,以后行同样方案同期放化疗,仍然每3周为1个化疗周期,共2个疗程。对照组(TP组)30例,采用顺铂(30 mg/m2静脉滴注第1~3天)代替奈达铂,其余治疗方法与实验组相同。结果诱导化疗2个周期后评价疗效:鼻咽部原发灶有效率实验组和对照组分别是78.6%和73.3%,P>0.05,差异无统计学意义;颈部淋巴结转移灶有效率实验组和对照组分别是82.1%和80.0%,P>0.05,差异无统计学意义。治疗后3个月鼻咽原发灶和颈部淋巴结转移灶的有效率均是100%。不良反应显示实验组和对照组白细胞减少的发生率分别为50.0%(14/28)和86.7%(13/15)(P=0.02),差异有统计学意义;贫血发生率分别为17.9%(5/28)和53.3%(8/15)(P=0.02),差异有统计学意义;血小板下降的发生率分别为42.9%(12/28)和20.0%(3/15)(P=0.09),差异无统计学意义。肝肾功能损害差异无统计学意义;恶心呕吐发生率实验组明显低于对照组,差异有统计学意义;体重下降(>10%)的发生率实验组明显低于对照组,差异有统计学意义。结论奈达铂联合紫杉醇结合同步放疗治疗局部晚期鼻咽癌疗效确切,且患者耐受性良好。 展开更多
关键词 奈达铂 顺铂 紫杉醇 同步放化疗 鼻咽癌
下载PDF
鼻咽癌癌变的分子机理 被引量:33
19
作者 李桂源 刘华英 +2 位作者 周鸣 周后德 李小玲 《生物化学与生物物理进展》 SCIE CAS CSCD 北大核心 2006年第10期922-931,共10页
鼻咽癌是一种多基因遗传性肿瘤,在中国南方和国外中国南方移民及后裔中发病率极高,严重危害了我国南方地区人民生命健康.对于这样一种具有明显民族聚集现象和地域差异的恶性肿瘤,目前认为其病理发病机制与遗传和环境因素的共同作用密切... 鼻咽癌是一种多基因遗传性肿瘤,在中国南方和国外中国南方移民及后裔中发病率极高,严重危害了我国南方地区人民生命健康.对于这样一种具有明显民族聚集现象和地域差异的恶性肿瘤,目前认为其病理发病机制与遗传和环境因素的共同作用密切相关.现主要阐述鼻咽癌作为一种多基因遗传性肿瘤的病因发病机制,初步建立鼻咽癌易感基因群的概念和鼻咽癌发生发展过程中易感基因群主导的多阶段性多米诺骨牌效应分子机制假说,为寻找鼻咽癌遗传易感风险因子,筛选鼻咽癌高危人群以及探索鼻咽癌靶向性及个体化的诊断和治疗手段奠定实验与理论基础. 展开更多
关键词 鼻咽癌 病因发病机制 易感基因群 多阶段性多米诺骨牌效应
下载PDF
Treatment outcomes for different subgroups of nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy 被引量:40
20
作者 Sheng-Fa Su 1,2,3,Fei Han 1,2,Chong Zhao 1,2,Ying Huang 1,2,Chun-Yan Chen 1,2,Wei-Wei Xiao 1,2,Jia-Xin Li 1,2 and Tai-Xiang Lu 1,2 1 State Key Laboratory of Oncology in South China,Guangzhou,Guangdong 510060,P.R.China 2 Department of Radiation Oncology,Sun Yat-sen University Cancer Center,Guangzhou,Guangdong 510060,P.R.China 3 Department of Oncology,Guiyang Medical College Hospital,Tumor Hospital of Guizhou,Guiyang,Guizhou 550003,P.R.China. 《Chinese Journal of Cancer》 SCIE CAS CSCD 北大核心 2011年第8期565-573,共9页
Although many studies have investigated intensity-modulated radiation therapy (IMRT) for nasopharyngeal carcinoma (NPC),sample sizes in the reported studies are usually small and different in outcomes in different T a... Although many studies have investigated intensity-modulated radiation therapy (IMRT) for nasopharyngeal carcinoma (NPC),sample sizes in the reported studies are usually small and different in outcomes in different T and N subgroups are seldom analyzed.Herein,we evaluated the outcomes of NPC patients treated with IMRT and further explored treatment strategy to improve such outcome.We collected clinical data of 865 NPC patients treated with IMRT alone or in combination with chemotherapy,and classified all cases into the following prognostic categories according to different TNM stages:early stage group (T1-2N0-1M0),advanced local disease group (T3-4N0-1M0),advanced nodal disease group (T1-2N2-3M0),and advanced locoregional disease group (T3-4N2-3M0).The 5-year overall survival (OS),local relapse-free survival (LRFS),and distant metastases-free survival (DMFS) were 83.0%,90.4%,and 84.0%,respectively.The early disease group had the lowest treatment failure rate,with a 5-year OS of 95.6%.The advanced local disease group and advanced nodal disease group had similar failure pattern and treatment outcomes as well as similar hazard ratios for death (4.230 and 4.625,respectively).The advanced locoregional disease group had the highest incidence of relapse and death,with a 5-year DMFS and OS of 62.3% and 62.2%,respectively,and a hazard ratio for death of 10.402.Comparing with IMRT alone,IMRT in combination with chemotherapy provided no significant benefit to locoregionally advanced NPC.Our results suggest that the decision of treatment strategy for NPC patients should consider combinations of T and N stages,and that IMRT alone for early stage NPC patients can produce satisfactory results.However,for advanced local,nodal,and locoregional disease groups,a combination of chemotherapy and radiotherapy is recommended. 展开更多
关键词 放射治疗 强度调制 鼻咽癌 患者 调控 样本大小 临床资料 结合治疗
下载PDF
上一页 1 2 250 下一页 到第
使用帮助 返回顶部